Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 10/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576095 | 0.83 | POLQ (0.52) | POLQCHRM2ADRA2AADRA2BDRD1 | |
| SCHEMBL5633706 | 0.79 | POLQ (0.48) | POLQPPARGPPARDPPARALMNA | |
| SCHEMBL5632125 | 0.79 | POLQ (0.48) | POLQCYP2C9CYP2C8CYP2B6CYP2C19 | |
| SCHEMBL5631214 | 0.79 | POLQ (0.50) | POLQCYP2C9CYP2C8CYP2B6CYP2C19 | |
| SCHEMBL4575799 | 0.78 | HRH1 (0.52) | POLQCHRM2ADRA2AADRA2BDRD1 | |
| SCHEMBL4575631 | 0.77 | PPARA (0.54) | POLQPPARGPPARDPPARALMNA | |
| SCHEMBL5632042 | 0.76 | POLQ (0.39) | POLQSLC6A2SLC6A4PPARGPPARD | |
| SCHEMBL5678630 | 0.75 | PPARA (0.42) | POLQPPARGPPARDPPARA | |
| SCHEMBL5675367 | 0.75 | PPARD (0.45) | POLQCYP2C9CYP2C19PPARGPPARD | |
| SCHEMBL5632540 | 0.74 | NR1H2 (0.47) | POLQCYP2C9PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613326-B1 | (3-{3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO]-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1613326-A1 | (3-{3-´(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | KALYPSYS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004093879-A1 | (3-{3-‘(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | PPARG, PPARA, PPARD | POLQ 2463/4885CHRM2 1005/4885ADRA2A 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.